Yabe Kuniaki, Yamamoto Yasuko, Takemura Masao, Hara Takeshi, Tsurumi Hisashi, Serrero Ginette, Nabeshima Toshitaka, Saito Kuniaki
Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, Aichi, Japan.
A&T corporation, Kanagawa, Japan.
Heliyon. 2021 Jan 8;7(1):e05849. doi: 10.1016/j.heliyon.2020.e05849. eCollection 2021 Jan.
Progranulin is an autocrine growth factor that promotes proliferation, migration, invasion, and chemoresistance of various cancer cells. These mechanisms mainly depend on the protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) pathway. Recent studies have shown that patients with hematopoietic cancer have elevated serum progranulin levels. Thus, the current study aimed to investigate the role of progranulin in hematopoietic cancer cells and how it modulates their proliferation. Both knockdown of progranulin and progranulin neutralizing antibody treatment inhibited proliferation in several human hematopoietic cancer cell lines. Moreover, progranulin depletion not only decreases the phosphorylation level of the Akt/mTOR pathway but also, surprisingly, increases the expression of transforming growth factor-beta (TGF-β) and phosphorylation of mothers against decapentaplegic homolog 2 (SMAD2) in Kasumi-1 cell. Furthermore, LY2109761, an inhibitor of TGF-β receptor type I/II kinase, and TGF-β neutralizing antibody blocked the inhibition of proliferation induced by progranulin depletion. These data provide new insights that progranulin alters cell proliferation via the TGF-β axis and progranulin could be a new therapeutic target for hematopoietic cancers.
颗粒蛋白前体是一种自分泌生长因子,可促进多种癌细胞的增殖、迁移、侵袭和化学抗性。这些机制主要依赖于蛋白激酶B(Akt)/雷帕霉素作用机制靶点(mTOR)信号通路。最近的研究表明,血液系统癌症患者的血清颗粒蛋白前体水平升高。因此,本研究旨在探讨颗粒蛋白前体在血液系统癌细胞中的作用及其调节细胞增殖的机制。颗粒蛋白前体的敲低和颗粒蛋白前体中和抗体处理均抑制了几种人类血液系统癌细胞系的增殖。此外,颗粒蛋白前体的缺失不仅降低了Akt/mTOR信号通路的磷酸化水平,而且令人惊讶的是,还增加了Kasumi-1细胞中转化生长因子-β(TGF-β)的表达以及母系抗五体不全同源蛋白2(SMAD2)的磷酸化。此外,I/II型TGF-β受体激酶抑制剂LY2109761和TGF-β中和抗体可阻断颗粒蛋白前体缺失诱导的增殖抑制。这些数据提供了新的见解,即颗粒蛋白前体通过TGF-β轴改变细胞增殖,颗粒蛋白前体可能是血液系统癌症的一个新的治疗靶点。